118-LB: Preclinical Development of IDG-16177 as a Potent GPR40 Agonist for Treatment of Type 2 Diabetes
2000 ◽
Vol 248
(6)
◽
pp. 492-500
◽
Keyword(s):
Keyword(s):
Keyword(s):